[go: up one dir, main page]

BR9502797A - Complexos de análogo de insulina-protamina suas formulações farmaceuticas parenterais processos para preparação dos ditos análogos e das formulações farmacêuticas e cristais de insulina-protamina - Google Patents

Complexos de análogo de insulina-protamina suas formulações farmaceuticas parenterais processos para preparação dos ditos análogos e das formulações farmacêuticas e cristais de insulina-protamina

Info

Publication number
BR9502797A
BR9502797A BR9502797A BR9502797A BR9502797A BR 9502797 A BR9502797 A BR 9502797A BR 9502797 A BR9502797 A BR 9502797A BR 9502797 A BR9502797 A BR 9502797A BR 9502797 A BR9502797 A BR 9502797A
Authority
BR
Brazil
Prior art keywords
insulin
pharmaceutical formulations
protamine
analogues
preparation
Prior art date
Application number
BR9502797A
Other languages
English (en)
Inventor
Felippis Michael Rosario De
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22989963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9502797(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9502797A publication Critical patent/BR9502797A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9502797A 1994-06-16 1995-06-14 Complexos de análogo de insulina-protamina suas formulações farmaceuticas parenterais processos para preparação dos ditos análogos e das formulações farmacêuticas e cristais de insulina-protamina BR9502797A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,633 US5461031A (en) 1994-06-16 1994-06-16 Monomeric insulin analog formulations

Publications (1)

Publication Number Publication Date
BR9502797A true BR9502797A (pt) 1996-03-12

Family

ID=22989963

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9502797A BR9502797A (pt) 1994-06-16 1995-06-14 Complexos de análogo de insulina-protamina suas formulações farmaceuticas parenterais processos para preparação dos ditos análogos e das formulações farmacêuticas e cristais de insulina-protamina

Country Status (37)

Country Link
US (3) US5461031A (pt)
JP (1) JP3812962B2 (pt)
KR (1) KR100386038B1 (pt)
CN (1) CN1145641C (pt)
AT (1) AT408611B (pt)
BE (1) BE1009409A5 (pt)
BR (1) BR9502797A (pt)
CA (1) CA2151564C (pt)
CH (2) CH689934A5 (pt)
CO (1) CO4410204A1 (pt)
CZ (1) CZ294556B6 (pt)
DE (1) DE19521753B4 (pt)
DK (1) DK176213B1 (pt)
ES (1) ES2091728B1 (pt)
FI (1) FI118208B (pt)
FR (1) FR2721215B1 (pt)
GB (1) GB2290294B (pt)
GR (1) GR1002494B (pt)
HU (1) HU218943B (pt)
IE (1) IE68852B1 (pt)
IL (1) IL114153A (pt)
IT (1) IT1276722B1 (pt)
LU (1) LU88627A1 (pt)
MY (1) MY116831A (pt)
NL (2) NL1000565C2 (pt)
NO (1) NO320808B1 (pt)
NZ (1) NZ272360A (pt)
PE (1) PE34496A1 (pt)
PL (1) PL183284B1 (pt)
PT (1) PT101723B (pt)
RO (1) RO115124B1 (pt)
SE (1) SE509295C2 (pt)
SI (1) SI9500199A (pt)
TW (1) TW347334B (pt)
UA (1) UA34468C2 (pt)
YU (1) YU39795A (pt)
ZA (1) ZA954941B (pt)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5888477A (en) * 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
EP1607086A1 (en) * 1993-01-29 2005-12-21 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US6131567A (en) * 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
WO1997002043A1 (en) * 1995-06-30 1997-01-23 Novo Nordisk A/S Prevention of a disease having the characteristics of diabetes
RU2182015C2 (ru) * 1996-06-20 2002-05-10 Ново Нордиск А/С ПРЕПАРАТ ИНСУЛИНА, СОДЕРЖАЩИЙ NaCl, ПАРЕНТЕРАЛЬНАЯ ГОТОВАЯ ФОРМА, СПОСОБ ПОВЫШЕНИЯ ХИМИЧЕСКОЙ СТАБИЛЬНОСТИ ПРЕПАРАТА ИНСУЛИНА
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
AU5749198A (en) * 1997-02-07 1998-08-26 Novo Nordisk A/S Crystallisation of proteins
DK1283051T3 (da) * 1997-06-13 2006-10-16 Lilly Co Eli Stabile insulinformuleringer
ZA984697B (en) * 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
KR20010024556A (ko) 1997-10-24 2001-03-26 피터 지. 스트링거 불용성 인슐린 조성물
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
US20010053761A1 (en) * 1998-01-08 2001-12-20 Dimarchi Richard Dennis Method for administering aspb28-human insulin
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
EP1346726A4 (en) * 2000-12-25 2004-09-15 Shiseido Co Ltd Sympathetic-activating perfume composition
DK1772464T3 (da) * 2001-02-09 2009-12-14 Genentech Inc Fremgangsmåder til identificering af indirekte agonister af IGF-1
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US7238663B2 (en) * 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
CN1571676A (zh) * 2001-10-19 2005-01-26 伊莱利利公司 Glp－1和胰岛素的双相混合物
WO2003053460A1 (en) * 2001-12-19 2003-07-03 Eli Lilly And Company Crystalline compositions for controlling blood glucose
US7601688B2 (en) * 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
EA014887B1 (ru) 2003-06-17 2011-02-28 Сембайосиз Джинетикс Инк. Способ экспрессии инсулина в семенах растения, способ получения семян растений, содержащих инсулин, и растения, способные производить семена, содержащие инсулин
US20050054818A1 (en) * 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
US20060241019A1 (en) * 2003-07-25 2006-10-26 Bridon Dominique P Long lasting insulin derivatives and methods thereof
AU2005209199B2 (en) * 2004-01-16 2008-09-11 Biodel Inc. Sublingual drug delivery device
PT1740154E (pt) * 2004-03-12 2009-09-11 Biodel Inc Composições de insulina com absorção melhorada
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US7872095B2 (en) 2004-07-19 2011-01-18 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
KR20070085227A (ko) * 2004-08-09 2007-08-27 앨리오스 바이오파마 인크. 합성 초글리코실화, 프로테아제 저항성 폴리펩티드 변이체,경구 제제 및 이를 이용한 방법
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
CA2581798A1 (en) * 2004-10-05 2006-04-13 Petter Lybeck A pharmaceutical formulation comprising crystalline insulin and dissolved insulin
JP4874989B2 (ja) 2004-11-22 2012-02-15 ノヴォ ノルディスク アー／エス 可溶性で安定なインスリン含有調合物
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
CN100371346C (zh) * 2005-12-14 2008-02-27 浙江大学 人工合成胰岛素模拟肽及其应用
WO2007096431A1 (en) * 2006-02-27 2007-08-30 Novo Nordisk A/S Insulin derivatives
US7718609B2 (en) * 2006-04-12 2010-05-18 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
CN101062948B (zh) * 2006-04-29 2010-05-12 上海生物泰生命科学研究有限公司 单体速效胰岛素及其制法和用途
WO2008124522A2 (en) * 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
CN101939023B (zh) 2007-10-16 2016-08-03 百康有限公司 可经口给药的固体药物组合物及其方法
MX2010007342A (es) * 2008-01-04 2010-08-26 Biodel Inc Formulaciones de insulina para la liberacion de insulina como una funcion de los niveles de glucosa en el tejido.
CN102209541B (zh) 2008-09-08 2016-05-18 小利兰·斯坦福大学托管委员会 醛脱氢酶活性调节剂和其使用方法
US8389522B2 (en) 2008-10-28 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
JP2012516340A (ja) 2009-01-28 2012-07-19 スマートセルズ・インコーポレイテツド 合成コンジュゲートおよびその使用
EP2391218B1 (en) * 2009-01-28 2020-03-18 Smartcells, Inc. Conjugate based systems for controlled drug delivery
CN102316892B (zh) 2009-02-12 2014-06-04 西马生物医学计划公司 心肌营养素-1用于治疗代谢病的用途
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
EP2408808A4 (en) 2009-03-20 2015-05-06 Smartcells Inc TERMINAL-FUNCTIONALIZED CONJUGATES AND THEIR USE
HUP0900482A2 (en) * 2009-08-03 2011-03-28 Cera Med Kft Pharmaceutical formulation for oral administration
US9074015B2 (en) 2010-07-28 2015-07-07 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
WO2012074883A1 (en) * 2010-11-24 2012-06-07 Durect Corporation Biodegradable drug delivery composition
WO2012098462A1 (en) 2011-01-20 2012-07-26 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
EP2925345B1 (en) 2012-12-03 2018-09-05 Merck Sharp & Dohme Corp. Method for making o-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
WO2014160185A2 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
BR112016007176A2 (pt) 2013-10-04 2018-01-23 Merck Sharp & Dohme conjugado, composição, usos de um conjugado e de uma composição, e, método para tratar um indivíduo que tem diabete
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
SG11201604708VA (en) * 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
BR112016016290A2 (pt) 2014-01-13 2017-10-03 Thermalin Diabetes Llc Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
WO2017163159A1 (en) 2016-03-21 2017-09-28 Wockhardt Limited Biphasic pharmaceutical composition of insulin human
MX2020001525A (es) 2017-08-24 2020-03-20 Novo Nordisk As Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
WO2019125878A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
EP3740212A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
CN110063932A (zh) * 2019-04-12 2019-07-30 浙江大学 一种多肽蛋白类药物的缓释组合物制剂及其制备方法
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
KR20220161422A (ko) 2020-03-31 2022-12-06 프로토머 테크놀로지스 인크. 비시날 디올에 대한 선택적인 반응을 위한 접합체
JP2024500284A (ja) 2020-11-19 2024-01-09 プロトマー・テクノロジーズ・インコーポレイテッド 芳香族ホウ素含有化合物及びインスリン類似体
AU2023272483A1 (en) 2022-05-18 2024-12-12 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2801953A (en) * 1952-02-28 1957-08-06 Hoechst Ag Process of preparing crystallized insulin preparations
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
DK119785D0 (da) * 1985-03-15 1985-03-15 Nordisk Gentofte Insulinpraeparat
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ223630A (en) * 1987-02-25 1989-11-28 Novo Industri As Insulin derivative and pharmaceutical compositions
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
ATE93238T1 (de) * 1988-07-20 1993-09-15 Novo Nordisk As Menschliche insulinanalage und zubereitungen daraus.
JPH04502465A (ja) * 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
IL93282A (en) * 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
DE69416409T2 (de) * 1993-06-21 1999-09-16 Novo Nordisk A/S, Bagsvaerd Asp-b28-insulinkristalle
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations

Also Published As

Publication number Publication date
GB2290294A (en) 1995-12-20
MY116831A (en) 2004-04-30
ZA954941B (en) 1996-12-17
YU39795A (sh) 1998-05-15
GB9512105D0 (en) 1995-08-09
IL114153A (en) 2000-09-28
HU9501717D0 (en) 1995-08-28
JPH083064A (ja) 1996-01-09
CH689934A5 (de) 2000-02-15
SE9502168L (sv) 1995-12-17
JP3812962B2 (ja) 2006-08-23
ATA101795A (de) 2001-06-15
HU218943B (hu) 2001-01-29
DK176213B1 (da) 2007-02-12
GR1002494B (el) 1996-12-12
DE19521753B4 (de) 2009-07-23
ITMI951277A0 (it) 1995-06-14
US5650486A (en) 1997-07-22
NO952356D0 (no) 1995-06-14
CN1116629A (zh) 1996-02-14
TW347334B (en) 1998-12-11
SE9502168D0 (sv) 1995-06-14
HUT71908A (en) 1996-02-28
CZ154395A3 (en) 1996-02-14
AT408611B (de) 2002-01-25
DE19521753A1 (de) 1995-12-21
SE509295C2 (sv) 1999-01-11
CN1145641C (zh) 2004-04-14
FI118208B (fi) 2007-08-31
NO320808B1 (no) 2006-01-30
FR2721215A1 (fr) 1995-12-22
FI952932L (fi) 1995-12-17
NL1000565A1 (nl) 1995-12-18
US5461031A (en) 1995-10-24
CA2151564C (en) 2003-02-11
CO4410204A1 (es) 1997-01-09
LU88627A1 (fr) 1996-02-01
FI952932A0 (fi) 1995-06-14
IE950435A1 (en) 1995-12-27
NZ272360A (en) 1997-02-24
UA34468C2 (uk) 2001-03-15
NO952356L (no) 1995-12-18
IE68852B1 (en) 1996-07-24
NL1000565C2 (nl) 1996-12-03
DK67695A (da) 1995-12-17
CH693019A5 (de) 2003-01-31
ES2091728B1 (es) 1998-02-01
CA2151564A1 (en) 1995-12-17
KR960000923A (ko) 1996-01-25
ITMI951277A1 (it) 1996-12-14
PT101723B (pt) 1997-02-28
NL1004643A1 (nl) 1996-12-17
RO115124B1 (ro) 1999-11-30
PT101723A (pt) 1995-12-29
SI9500199A (en) 1996-02-29
US5747642A (en) 1998-05-05
CZ294556B6 (cs) 2005-02-16
PL183284B1 (pl) 2002-06-28
NL1004643C2 (nl) 1997-02-12
KR100386038B1 (ko) 2003-08-27
PE34496A1 (es) 1996-10-01
IT1276722B1 (it) 1997-11-03
PL309100A1 (en) 1995-12-27
IL114153A0 (en) 1995-10-31
ES2091728A1 (es) 1996-11-01
FR2721215B1 (fr) 1997-08-14
BE1009409A5 (fr) 1997-03-04
GB2290294B (en) 1999-03-17

Similar Documents

Publication Publication Date Title
BR9502797A (pt) Complexos de análogo de insulina-protamina suas formulações farmaceuticas parenterais processos para preparação dos ditos análogos e das formulações farmacêuticas e cristais de insulina-protamina
BR9700829A (pt) Uso de interferon consensus humano para a produção de um medicamento
MX17752A (es) Formulaciones farmaceuticas y procedimiento para prepararlas
FR2636532B1 (fr) Compositions pharmaceutiques
MX9206953A (es) Composiciones fisiologicas de lagrima y metodos para su preparacion
KR950703566A (ko) 티에노디아제핀 화합물 및 그의 의약 용도[thienodiazepine compound and medicinal use thereof]
NO922005D0 (no) Farmasoeytiske preparater
ITMI950529A0 (it) Composizioni farmaceutiche e procedimento per la loro preparazione
NO954486D0 (no) Farmasöytiske formuleringsgrunnlag
DK489189D0 (da) Farmaceutisk praeparat
MX9200105A (es) Derivados de cefem y procedimientos para su preparacion
EE9600139A (et) Farmatseutilised preparaadid ja ravimid endoteelsete düsfunktsioonide vältimiseks ja raviks
IT1239542B (it) Composizione farmaceutica comprendente piroxicam e procedimento per lasua preparazione
FI913100A7 (fi) Farmaseuttiset valmisteet
MX14533A (es) Procedimiento para la preparacion de compuestos farmaceuticos
DK603988D0 (da) Farmaceutisk praeparat
MX9100357A (es) Composiciones farmaceuticas estabilizadas y procedimiento para su preparacion
MX9100742A (es) Composicion farmaceutica y procedimiento para su preparacion
DK496889A (da) Peptidholdigt farmaceutisk praeparat
MX9101081A (es) Compuestos fungicidamente activos y procedimiento para su preparacion
DK336489D0 (da) Farmaceutisk praeparat
EE04095B1 (et) Ketoliidide ja nende farmatseutiliselt vastuvõetavate soolade kasutamine farmatseutiliste kompositsioonide valmistamiseks
ITMI951417A0 (it) Composizioni farmaceutiche e procedimento per la loro preparazione
BR9509055A (pt) Imidazoloquinoxalinona uso da mesma e composiçao farmacêutica
FI951155A7 (fi) Farmaseuttinen valmiste

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 14/06/2015